Novartis has announced positive results from three Phase II trials showing that AIN457 (secukinumab) produced a quick and significant improvement of symptoms in patients with moderate-to-severe plaque psoriasis. The results were presented at the annual European Academy of Dermatology and Venereology (EADV) Congress, in Lisbon, Portugal.

In one study, 81% of patients receiving AIN457 150mg subcutaneously once a month experienced at least a 75% improvement of psoriasis signs and symptoms as measured by PASI (Psoriasis Area and Severity Index) vs 9% for placebo at week 12 (p<0.001). In another study, results also showed that 83% of patients who were given an intravenous starting dose of AIN457 experienced at least a 75% improvement of symptoms vs 10% for placebo[3]. A third study showed that receiving AIN457 in the first month was beneficial to 55% of patients vs 2% for placebo at week 12.

"These data suggest that AIN457 could potentially bring about a considerable improvement in the lives of patients with moderate-to-severe plaque psoriasis by producing a rapid response and substantial relief of symptoms," said Dr. Kim Papp, Dermatologist and Director of Research at Probity Medical Research, Waterloo, Ontario, Canada, and one of the investigators of the studies. "Plaque psoriasis is a disruptive and often painful chronic immune disease and there is a critical need for new treatment options that combine long-term efficacy with a favourable safety profile."

AIN457 is a fully human, targeted monoclonal antibody that specifically and rapidly binds to and neutralizes interleukin-17A (IL-17A), an inflammatory cytokine implicated in a number of immune-mediated diseases, including psoriasis.

"We are encouraged by these positive Phase II results and look forward to receiving the results of larger-scale and longer-term Phase III studies with AIN457 which began this year," said John Hohneker, Global Head of Development for Integrated Hospital Care at Novartis. "Novartis is committed to providing new treatment options for patients with moderate-to-severe plaque psoriasis, who face significant daily physical discomfort as well as the serious psychological impact of living with this disease."

Source: novartis.com

A mutation in the interleukin-36 receptor antagonist (IL-36Ra) has been identified as a cause of the unregulated secretion of inflammatory cytokines and generalized pustular psoriasis (GPP) by a multicenter consortium.

Their research was presented here at the 12th International Congress of Human Genetics and the 61st American Society of Human Genetics Annual Meeting.

Asma Smahi, PhD, from Hôpital Necker-Enfants Malades, Paris, France, and colleagues identified a highly significant linkage to an interval of 1.2 Mb on chromosome 2q13-q14.1, as well as a homozygous missense mutation in the IL-36Ra, an antiinflammatory cytokine gene.

"We performed homozygosity mapping and direct sequencing on 9 Tunisian multiplex families with autosomal recessive GPP," Dr. Smahi reported, "and results reveal a key role for IL-36Ra-regulated autoinflammation in the pathogenesis of GPP via unregulated IL-1 family inflammatory cytokine secretion in the skin."

Chromosome Region Pinpointed

As Dr. Smahi told Medscape Medical News, they first identified a chromosome region in which the mutation was implicated, and then sequenced the gene located in that region. "What we found specifically was a mutation in the gene that encodes for the IL-36Ra, and in vitro studies on keratinocytes from our patients showed that this mutation was responsible for loss of function of this receptor."

Because this receptor functions as an inhibitor, "inflammation is not regulated," she added, "and this leads to GPP and potentially other forms of psoriasis."

Importantly, a separate group of researchers from London have identified another mutation in the same gene in another group of families with GPP living in the United Kingdom — suggesting that there is a common pathway giving rise to GPP, and psoriatic diseases in general.

These observations could have direct therapeutic implications. As Dr. Smahi explained, they previously identified another autoinflammatory syndrome — deficiency of IL-1 Ra, which has been shown to respond to treatment with a targeted IL-1 Ra, restoring the phenotype in patients with this deficiency.

"This gives us good reason to believe that IL-36Ra treatment will restore the impaired function of this receptor [giving rise to GPP] and stop the upregulation of inflammatory cytokines," she said.

Hervé Bachelez, MD, PhD, from teh service de dermatologie, Hôpital Saint-Louis, Paris, France, told Medscape Medical News that from its initial description in 1910, the GPP form of psoriasis has been shown to be a rare, life-threatening variant displaying a filiation with plaque-type psoriasis — the most frequent form of psoriasis — with which it is combined in a single patient in roughly one quarter of cases.

"Likewise, studying genetic and molecular mechanisms underlying these rare variants may identify new key pathogenic mechanisms and therapeutic targets shared by GPP and plaque-type psoriasis (also called psoriasis vulgaris)," he said. Our results and those from the London team support the therapeutic targeting of the IL-36 receptor pathway as an appealing strategy in familial and sporadic cases of GPP, he explained.

Furthermore, Dr. Bachelez added, even though genetic abnormalities of IL-Ra have not been shown in patients with psoriasis vulgaris so far, "there have been convincing demonstrations that both IL-36 and its receptor are activated in psoriatic plaques from patients with psoriasis vulgaris. Altogether, these recent insights emphasize the key role of innate immunity in psoriatic inflammation."

Source: medscape.com

New findings from the TRANSIT study were presented today at the 20th European Academy of Dermatology and Venereology (EADV) congress, which showed treatment with STELARA® (ustekinumab) is well-tolerated and effective in patients with moderate to severe plaque psoriasis inadequately responsive to methotrexate therapy. Health-related quality of life was also significantly improved according to the study results reported.

The TRANSIT study, a 52 week, open-label, phase IV study of 489 patients, was designed to compare two methods of transitioning patients from methotrexate to ustekinumab. The first was discontinuation of methotrexate with immediate initiation of ustekinumab and the second was initiation of ustekinumab with overlap and gradual dose reduction of methotrexate over four weeks. Results up to week 16 were presented today at the EADV congress.

The primary endpoint of the TRANSIT study was the proportion of patients experiencing at least 1 treatment-emergent adverse event through week 12 in arm 1 versus arm 2.  The number and types of adverse events were similar in the two treatment arms. Serious adverse events were infrequent regardless of the transition strategy: 2.9% of patients in the methotrexate immediate cessation arm versus 2.0% of patients in the methotrexate gradual withdrawal arm. Substantial improvement in efficacy was also observed above and beyond the results patients had achieved on methotrexate, which all patients had been receiving for at least 8 consecutive weeks prior to baseline, and which was considered to be inadequately effective.  Through week 12, the majority of patients in both arms achieved a Psoriasis Global Assessment (PGA) rating of 'cleared' or 'minimal' (65.3% in the methotrexate immediate cessation arm and 69.5% in the methotrexate gradual withdrawal arm). The median Psoriasis Area and Severity Index (PASI) score decreased from approximately 15 in both arms at baseline to 2.9 in the methotrexate immediate cessation arm versus 2.8 in the methotrexate gradual withdrawal arm.

Improvements in health-related quality of life, as assessed by the Dermatology Life Quality Index (DLQI), were observed as early as week four in both arms of the study. Over the study period of 16 weeks, the mean improvement in DLQI was demonstrated by a reduction from 8.0 in the immediate cessation arm and 9.0 in the gradual withdrawal arm to a score of 1.0 in both arms, a clinically meaningful improvement in health-related quality of life.Substantial improvement in the EuroQOL-5D Visual Analogue Scale (EQ-5D VAS) was also observed in both arms.

"Until now there has been very limited data on how to safely and effectively transition patients with moderate to severe plaque psoriasis from conventional systemic agents to biologics," said Professor Carle Paul, University of Toulouse, France and one of the lead investigators for the TRANSIT study. "Results from the TRANSIT study are important because they further advance our understanding of biologics, not just in terms of efficacy, safety and tolerability, but also health-related quality of life. The health-related quality of life improvements are particularly notable given that patients were already being treated with methotrexate when they entered the study, and over a quarter of patients included in the study had been previously treated with other biologic therapies."

Also presented at EADV were findings from pooled analyses of the ongoing ustekinumab psoriasis clinical development programme (which includes the Phase 2 trial, and the Phase 3 PHOENIX 1, PHOENIX 2 and ACCEPT trials). Data showed that the safety profile of ustekinumab and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment. More than 1100 patients had been treated for at least three years with ustekinumab and more than 600 patients had been treated for at least four years, representing a total of nearly 6800 patient years (PY).

"Biological therapies are a valuable advancement in the treatment of moderate to severe psoriasis. To support dermatologists in their decision-making about the most suitable treatment option for patients, it is important to have long-term data on available therapies. This pooled 4-year safety data provides a growing and significant body of evidence about the role ustekinumab can play in the management of this chronic, life-long condition", said Professor Christopher Griffiths, University of Manchester, UK, and lead trial investigator for the ACCEPT study.

Methotrexate is not a disease-modifying antirheumatic drug in psoriatic arthritis, despite how well it works in psoriasis, according to Dr. Christopher T. Ritchlin.

Methotrexate is the most widely used drug in the world for psoriatic arthritis (PsA), based on almost no supporting evidence. There have been only two published double-blind, randomized, controlled trials of methotrexate in PsA done over the last 20 years, and both were underpowered and used a low dose of methotrexate (10 mg/week), said Dr. Ritchlin, professor of medicine and director of the clinical immunology research centre at the University of Rochester (N.Y.).

A still-unpublished study that was presented at the annual meeting of the American College of Rheumatology in 2010 showed that methotrexate was not more effective than placebo in PsA The study involved 221 patients who were given 15 mg/week of methotrexate or placebo for 6 months. About 65% of subjects in each group dropped out. The primary outcome measure was the psoriatic arthritis response criteria (PsARC), which most rheumatologists do not think is a good outcome measure, Dr. Ritchlin said at the Perspectives in Rheumatic Diseases 2011 meeting.

At the end of 3 and 6 months of the study, there were no differences between methotrexate and placebo on the PsARC, the ACR 20 (the American College of Rheumatology scale based on a 20% improvement in certain parameters), the DAS28 (Disease Activity Score based on a 28-joint count), a sensitive joint count, a tender joint count, and the C-reactive protein level/erythrocyte sedimentation rates. Only the patient and physician global scores and the skin score showed significant improvement in the methotrexate group.

Indirect data supporting the inefficacy of methotrexate come from NOR-DMARD. These data show that 6 months of treatment with a tumor necrosis factor inhibitor (146 patients) had significantly greater beneficial effects on patients with PsA than did methotrexate.

The propensity toward liver disease is another reason not to use methotrexate in patients with PsA, said Dr. Ritchlin at the meeting, which was sponsored by Skin Disease Education Foundation. Methotrexate is hepatotoxic. Data on the findings of 169 liver biopsies that were done on 71 patients with psoriasis showed that methotrexate significantly increased the risk for stage 3 or 4 fibrosis.

How does it affect the internal organs of the body and brain tissues specifically?

So if you have had head injuries does it plaque inside the brain?

Thank you for having this forum.

I am grateful to be accepted. I have Guttate.
Waiting to find out if I have PA as well.

Not ready for the new drugs - too much trauma in my life - already, but as I get older I consider it.

Researchers at the 67th Annual Meeting of the American Society for Reproductive Medicine (ASRM) are presenting new information on conditions that can influence the timing of the menopausal transition.

Quote:Researchers at the University of Pennsylvania reviewed the records of more than 1.7 million women of reproductive age included in The Health Improvement Network (THIN), an electronic medical records database, to determine whether early menopause or premature ovarian failure is more prevalent in women diagnosed with psoriasis, rheumatoid arthritis, inflammatory bowel disease, or systemic lupus erythematosus.  They found that women with these conditions are two to five times more likely than unaffected women to go through menopause before the age of 45 or experience loss of ovarian function before the age of 40.

Posterior reversible encephalopathy syndrome (PRES), also known as reversible posterior leukoencephalopathy syndrome (RPLS), is a syndrome characterised by headache, confusion, seizures and visual loss. It may occur due to a number of causes, predominantly malignant hypertension, eclampsia and some medical treatments. On magnetic resonance imaging (MRI) of the brain, areas of edema (swelling) are seen. The symptoms tend to resolve after a period of time, although visual changes sometimes remain. It was first described in 1996.

The first case of RPLS in a 65-year-old woman who underwent Stelara therapy for psoriasis. Approximately 21/2 years after the patient began Stelara therapy, she experienced an acute onset of confusion, headache, nausea, vomiting, and seizures. Computed tomographic scans and magnetic resonance images of her head revealed characteristic findings, including white matter abnormalities consistent with edema in the absence of infarction. There was no evidence of vasospasm, thrombosis, or infection. Cerebrospinal fluid tests were negative for the JC virus. The patient improved clinically and was discharged 6 days after she presented to the emergency department. She made a full neurologic recovery, with a reversal of the radiologic findings.

Reversible posterior leukoencephalopathy syndrome is an increasingly recognized neurologic disorder that has been reported with the use of systemic and biologic agents to treat moderate to severe psoriasis. Although the relationship between RPLS and Stelara therapy remains unclear, this case emphasizes the need for dermatologists to recognize the syndrome's signs and symptoms and to refer patients promptly for evaluation and appropriate treatment if the clinical features of RPLS are suspected.

Source: archderm.ama-assn.org

Following a number of enquiries to the HPA from local environmental health practitioners, a multi-agency working group was established to produce guidance for this spa treatment. The working group was led by the HPA and included experts from the HPA, Health Protection Scotland, the Health & Safety Laboratory and local authorities. The guidance has been endorsed by the Chartered Institute of Environmental Health and the Royal Environmental Health Institute of Scotland.

Fish tank water has been shown to contain a number of microorganisms. Therefore, in a fish spa setting there is the potential for transmission of a range of infections, either from fish to person (during the nibbling process), water to person (from the bacteria that can multiply in water), or person to person (via water, surrounding surfaces and fish). However, the overall risk of infection is likely to be very low, if appropriate standards of hygiene are adhered to.

The fish spa working group concluded that those with weakened immune systems or underlying medical conditions, including diabetes and psoriasis, are likely to be at increased risk of infection and so fish pedicures are not recommended for such individuals. The working group advised that operators of fish spas should not promote treatment to these groups.

It’s important for salons to ensure the client has no underlying health conditions that could put them at risk, and that a thorough foot examination is performed, to make sure there are no cuts, grazes or existing skin conditions that could spread infection.

Dr Paul Cosford, Director of Health Protection Services at the HPA, added: “As with any beauty salon, it’s really important that strict standards of cleanliness are followed, to ensure that the risk of infection is kept to a minimum. If a member of the public is concerned about the level of cleanliness of a salon they visit, they should report this to their local Environmental Health department.”

Source: hpa.org.uk

Background
Alopecia areata (AA) is considered an autoimmune disease with undetermined pathogenesis. Age at onset predicts distinct outcomes. A nationwide study of the relationship of AA with associated diseases stratified by onset age has rarely been reported.

Objective
We sought to clarify the role of atopic and autoimmune diseases in AA, thereby better understanding its pathogenesis.

Methods
A total of 4334 patients with AA were identified from the National Health Insurance Database in Taiwan from 1996 to 2008. A national representative cohort of 784,158 persons served as control subjects.

Results
Among patients with AA, there were significant associations with vitiligo, lupus erythematosus, psoriasis, atopic dermatitis, autoimmune thyroid disease, and allergic rhinitis. Different ages at onset resulted in disparate comorbidities. Increased risk of atopic dermatitis (odds ratio [OR] 3.82, 95% confidence interval 2.67-5.45) and lupus erythematosus (OR 9.76, 95% confidence interval 3.05-31.21) were found in childhood AA younger than 10 years. Additional diseases including psoriasis (OR 2.43) and rheumatoid arthritis (OR 2.57) appeared at onset age 11 to 20 years. Most atopic and autoimmune diseases were observed at onset ages of 21 to 60 years. With onset age older than 60 years, thyroid disease (OR 2.52) was highly related to AA. Moreover, patients with AA had higher risk for more coexisting diseases than control subjects.

Conclusions
AA is related to various atopic and autoimmune diseases. Different associated diseases in each onset age group of AA can allow clinician to efficiently investigate specific comorbidities.

Moberg Derma AB (STO:MOB)(OMX: MOB) and Meda AB have entered into a license agreement covering rights for Nalox – Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.
Under the agreement, Meda is granted exclusive rights to market and sell Nalox in a large number of countries in Europe. Moberg Derma assumes production and supply responsibility. Over the past year, Meda has made Nalox market leader in the Nordic region.

The agreement encompasses several major markets, including Germany, France, Spain, United Kingdom, Austria, the Netherlands and Belgium.

“This agreement is a key step in the global launch of Nalox”, said Peter Wolpert, CEO of Moberg Derma. “Meda has proven to be the perfect partner in the Nordic region by quickly making Nalox into the market leader and we look forward to repeating this success story in several other markets through Meda’s strong sales organization in Europe”, concludes Wolpert.

Source: eyugoslavia.com

Physically demanding occupational tasks (eg, lifting heavy loads) and infections that required antibiotics are associated with psoriatic arthritis (PsA) in patients with psoriasis. There is an inverse association between cigarette smoking and PsA.

Eder and coworkers conducted a case-control study of patients with recent-onset PsA and patients with psoriasis but not arthritis (controls). They investigated a broad range of potential triggering factors and designed a questionnaire for assessing these exposures, which included physical trauma, infections, vaccinations to hepatitis A and B, emotional stress, female hormonal exposures, occupational exposures, smoking status, and alcohol consumption.

The proportion of smokers was lower in the PsA group than in the psoriasis group. Lifting cumulative loads of at least 100 lb/h was more common in the PsA group. A history of infectious diarrhea in the exposure time window under study was more common in the PsA group. After multivariate logistic regression, lifting cumulative loads of at least 100 lb/h, infections that required antibiotics, smoking, and injuries remained significantly associated with PsA. No association was found between PsA and alcohol consumption, vaccination, emotional stress, and female hormonal exposures.

Source: musculoskeletalnetwork.com

If you would like to add a link back to Psoriasis Club from your website using HTML here are some ready made links for you. just copy and paste your chosen code below.

If you would like something different please let me know.

For this logo ready to go just copy and paste the code below.

There is a sticky thread in this section "How did you find psoriasis club" but just as a matter of interest which search engine do you use ?

Google Yahoo Bing or another ?

A new survey of 3,000 Canadians living with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) reveals that Canadians feel that their inflammatory arthritis interferes with their overall happiness, and prevents them from enjoying many of their favourite activities.

The survey was conducted by Abbott to reveal the extent to which inflammatory arthritis affects the daily lives of people who live with these diseases. Arthritis and other rheumatic conditions currently affect nearly 4.5 million Canadians, with arthritis being among the top three most common chronic diseases in Canada.*

The economic burden of arthritis in Canada is estimated at $4.4 billion annually**. Among the survey respondents, 34% said that they have been living with their chronic illness for 20 or more years. Respondents indicated that their illness has affected their productivity level at work and home, with 48% stating that it prevents them from working full-time hours.

The study revealed some interesting facts about living with inflammatory arthritis:

73% said their chronic illness affected their day to day activities at home or at work.
42% of participants thought their chronic illness interfered with their hobbies or recreational activities.
67% of participants said they haven't been able to enjoy all the activities they used to do prior to the occurrence of their symptoms.
Women had a more negative outlook on their overall health than men with 42% of women stating they thought they were in good health compared to 44% of men.
48% said their chronic illness prevents them from working full-time hours.

Source: newswire.ca

Hiya is there any1 on Fumaderm?? I started this drug in August and had the odd flush and tummy cramp/upset 2 or 3 times a week which i could handle and was advised it would ease off the longer i was on it............ I started the highest dose on Monday (6 blue per day) OMG The cramps in my stomach are worse than havin a baby, the flushes are soo bad im in a freezing cold shower 2 or 3 times a day and anything i eat is just running thru me Ive been on cyclo & mtx never had any side effects and my skin was clear within 7weeks only downside to them are the day u stop taking them it cums back with a vengence so this is why my Consultant recommended Fumaderm as its long term but im thinking of giving up as the side effects are so bad and my skin has only got better slightly. Please tell me if any1 is suffering the same symptoms.

South Korean skincare products manufacturer NeoPharm has tied up with the UAE-based Japan Emirates Trading (JET) to introduce a skincare technology in the Middle East for the treatment of dry skin and other skin disorders.

A US FDA-approved company, NeoPharm was awarded the prestigious KOTRA award from the South Korean government for setting a benchmark in dermatological science by researching the unique, patented Multi Lamellar Emulsion (MLE) technology that mimics the human skin structure.

MLE has been specifically researched for the treatment of dry, sensitive and sun-damaged skin, as well as skin disorders such as Atopic Eczema, an inflammation of the skin which tends to flare-up from time to time, usually from early childhood, and Psoriasis.

Initially, six of the Atopalm products will be made available at pharmacies across the UAE, by Japan Emirates Trading, the exclusive distributor of the Atopalm range in the Middle East. The six products are Atopalm intensive moisturizing cream, Atopalm moisturizing body lotion, Atopalm moisturizing skin revitalizing complex, Atopalm moisturizing eye repair serum, Atopalm moisturizing hand treatment and Atopalm moisturizing facial cleansing foam.

Source: emirates247.com

When you register as a member you can read messages sent to you by other members but you can't send any until you have made 5 posts.

Click "Private Messages" in the green bar just below the menu. from here you can use the internal message system. it works similar to emails with an inbox, compose message, sent items, trash, etc.

You can also send another member a PM by clicking the PM image bottom left on a members post.

Keep an eye on your % of PM space used after 5 posts you can have 25 messages in your folders. after 10 posts you can have 50 messages in your folders. etc.

Please let me know if you are getting PMs from another member that you would class a spam, trolling, or bullying.  

Any questions please ask.

By default there are User titles/ranks. When you first join you are a "Newbie" after 5 posts you become a "Novice" and so on.

Bonus: As you move up through the ranks there are perks like using the PM system, starting polls, posting in certain sections, and more. Once you have made 10 Posts you can choose your own User title/rank or stick to the default ones as you progress. To use your own Title/Rank click "User CP" / "Edit Profile" and on the right hand side you see a new box "Custom User Title" make your choice scroll down and click "Update Profile"

There are other Titles/Ranks as you go on and some extra perks but I won't spoil it for you.

Not actually a treatment but definitely worth a try for soft clothes and shampoo. If you haven't heard of or tried these you should check them out. Just do a Google search for Soap Nuts. Shop around I have found the best quality and price in our supermarket.

So What Are They ?
They are a berry from the Sapindus tree. the berry is dried in the sun then cracked open to get the shell. it's actually the shell that you use. They have been used for washing for thousands of years by native people in Asia and Native Americans.

What Can They Be Used For ?
Just about anything to do with cleaning including. Use as a detergent, a personal cleanser and shampoo, a general purpose cleaner, car wash, pet wash, vegetable wash, carpet and upholstery cleaner.

Recipes
Laundry: Place 3-4 whole cracked shells (or equivalent in pieces) into a cotton bag or odd cotton sock, tie up or knot the top and place into the tub with your laundry.
Remove the nuts after the cycle has finished and let dry (if there's time!) before your next load.
The number of nuts you use depends on the size of your load and how dirty the items are, as well as the hardness of your water and efficiency of your machine.
For example, use four nuts for a large, dirty load, in an old washing machine using hard town water, and two to three nuts for a small or normal load in a modern machine using rainwater.
The temperature of the water is also a factor, as hot water will make the nuts release their surfactants quicker so you'll have to replace the nuts more frequently but the cleaning power will be stronger.
Washing your laundry in cold water is perfectly fine depending on how dirty your laundry load is. We recommend experimenting to find the best quantity required for your personal need s.
One lot of soapnuts can be reused until they lose their sticky, soapy feel and look pale and squishy on the inside, and are brittle when dry (4-6 times). When they are spent, throw them in the garden or compost.

Make your own Liquid Concentrate:
Place 100g of soapnuts with 3 litres of water in a large saucepan or stock pot (this will make 2 litres of liquid - you can make smaller amounts by using 2 cups of water and 4-6 nuts).
Bring to the boil, reduce heat and simmer for an hour or so. Strain the liquid through cloth and compost the nuts. Let cool. has approximately a 2 week shelf life in the kitchen, or at least a month in the refrigerator.
The concentrate will have a watery consistency and small dense suds. It does not contain foaming agents and thickeners like chemical detergents do, but it still has the cleaning power! To thicken the concentrate, add a little cornflour or glycerine.

Using the Liquid Concentrate.
laundry liquid (1-2 tbs in the detergent drawer)
hand soap (use in a foamy pump pack)
shampoo (replaces shampoo and conditioner together, try a spray bottle!)
pet shampoo (leaves hair soft and silky, will also repel fleas, mites, ticks, mosquitoes etc)
general purpose cleaner for the kitchen and bathroom (use with a cloth from the jar or spray bottle)
carpet cleaner (spray or sponge onto stain and blot clean)
dishwasher soap (liquid in dispenser section with optional 1tbs vinegar as a rinse aid)
pest spray (use spray bottle to spray bugs on plants)
glass cleaner (1tbs soapnut liquid, 1 tbs vinegar and 1 cup water)

They do work for laundry although stubborn stains are more difficult. the shampoo does work although you don't get any lather. Give them a go they are cheaper and friendlier than detergents.